CN1388247A - 一种增强细胞特异性目的基因表达的方法 - Google Patents
一种增强细胞特异性目的基因表达的方法 Download PDFInfo
- Publication number
- CN1388247A CN1388247A CN01118525A CN01118525A CN1388247A CN 1388247 A CN1388247 A CN 1388247A CN 01118525 A CN01118525 A CN 01118525A CN 01118525 A CN01118525 A CN 01118525A CN 1388247 A CN1388247 A CN 1388247A
- Authority
- CN
- China
- Prior art keywords
- gene
- cell
- promotor
- gal4
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000005728 strengthening Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 332
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 133
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 65
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 56
- 238000013518 transcription Methods 0.000 claims abstract description 55
- 230000035897 transcription Effects 0.000 claims abstract description 53
- 102100039556 Galectin-4 Human genes 0.000 claims description 69
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 claims description 69
- 201000011510 cancer Diseases 0.000 claims description 67
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 52
- 238000011282 treatment Methods 0.000 claims description 51
- 230000003213 activating effect Effects 0.000 claims description 50
- 108020004414 DNA Proteins 0.000 claims description 48
- 230000004927 fusion Effects 0.000 claims description 45
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims description 43
- 210000001519 tissue Anatomy 0.000 claims description 34
- 108091023040 Transcription factor Proteins 0.000 claims description 29
- 102000040945 Transcription factor Human genes 0.000 claims description 27
- 230000006907 apoptotic process Effects 0.000 claims description 19
- 108010017842 Telomerase Proteins 0.000 claims description 17
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 claims description 17
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 claims description 11
- 210000001161 mammalian embryo Anatomy 0.000 claims description 11
- 241001529453 unidentified herpesvirus Species 0.000 claims description 10
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 5
- 108050007852 Tumour necrosis factor Proteins 0.000 claims description 5
- 102000018594 Tumour necrosis factor Human genes 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 108090000328 Arrestin Proteins 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 102000003425 Tyrosinase Human genes 0.000 claims description 3
- 108060008724 Tyrosinase Proteins 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 229940088592 immunologic factor Drugs 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 210000003097 mucus Anatomy 0.000 claims description 3
- 101150061166 tetR gene Proteins 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 102000009122 CCAAT-Enhancer-Binding Proteins Human genes 0.000 claims description 2
- 108010048401 CCAAT-Enhancer-Binding Proteins Proteins 0.000 claims description 2
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 241000186216 Corynebacterium Species 0.000 claims description 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108700005090 Lethal Genes Proteins 0.000 claims description 2
- 108020004440 Thymidine kinase Proteins 0.000 claims description 2
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 2
- 102000000887 Transcription factor STAT Human genes 0.000 claims description 2
- 108050007918 Transcription factor STAT Proteins 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 230000002491 angiogenic effect Effects 0.000 claims description 2
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 230000001472 cytotoxic effect Effects 0.000 claims description 2
- 206010013023 diphtheria Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 102000015694 estrogen receptors Human genes 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- -1 il-1 2 Proteins 0.000 claims description 2
- 229940028885 interleukin-4 Drugs 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 86
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 230000005758 transcription activity Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 289
- 241000701161 unidentified adenovirus Species 0.000 description 151
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 44
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 43
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 43
- 239000005090 green fluorescent protein Substances 0.000 description 39
- 101150024147 bax gene Proteins 0.000 description 31
- 230000002068 genetic effect Effects 0.000 description 23
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 22
- 239000000872 buffer Substances 0.000 description 22
- 239000013598 vector Substances 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 239000000969 carrier Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- 241000700605 Viruses Species 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 15
- 108700012411 TNFSF10 Proteins 0.000 description 15
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 15
- 230000001665 lethal effect Effects 0.000 description 15
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 14
- 108700008625 Reporter Genes Proteins 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 101100369993 Mus musculus Tnfsf10 gene Proteins 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 230000002103 transcriptional effect Effects 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 238000010171 animal model Methods 0.000 description 10
- 101150036876 cre gene Proteins 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 241000699660 Mus musculus Species 0.000 description 9
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- 230000001276 controlling effect Effects 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 201000005296 lung carcinoma Diseases 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 108091035539 telomere Proteins 0.000 description 7
- 210000003411 telomere Anatomy 0.000 description 7
- 102000055501 telomere Human genes 0.000 description 7
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 6
- 101150064015 FAS gene Proteins 0.000 description 6
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 101150042537 dld1 gene Proteins 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 230000000452 restraining effect Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108010034949 Thyroglobulin Proteins 0.000 description 3
- 102000009843 Thyroglobulin Human genes 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108700025694 p53 Genes Proteins 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 229960002175 thyroglobulin Drugs 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 101150029662 E1 gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 101150060155 Dcc gene Proteins 0.000 description 1
- 101150005585 E3 gene Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101150077230 GAL4 gene Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101100437308 Homo sapiens BAX gene Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 241001068295 Replication defective viruses Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 108010053551 Sp1 Transcription Factor Proteins 0.000 description 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 1
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 1
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 1
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 1
- 102100030246 Transcription factor Sp1 Human genes 0.000 description 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000010441 gene drive Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
细胞株 | CEA | 半乳糖甘酶的活性(3组实验的平均值) | 增强倍数 | |
AD/CEA-LacZ | AD/CEA-GV16+AD/GT-LacZ | |||
DLD1 | 阳性 | 3.0×106 | 9.9×107 | 33 |
Lovo | 阳性 | 1.8×106 | 4.9×107 | 27 |
A549 | 阳性 | 2.0×106 | 9.1×107 | 45 |
HeLa | 阴性 | 9.5×104 | 6.2×105 | 6.5 |
成纤维细胞 | 阴性 | 4.1×104 | 3.4×105 | 8.3 |
细胞株 | 半乳糖甘酶的活性(3组实验的平均值) | 增强倍数 | |
AD/TERT-LacZ | AD/TERT-GV16加AD/GT-LacZ | ||
A549 | 6.3×104 | 2.2×107 | 349 |
H460 | 3.4×104 | 1.3×107 | 382 |
H1299 | 1.5×105 | 2.7×107 | 180 |
Lovo | 1.3×105 | 2.3×107 | 177 |
NHFB | 2.9×102 | 1.1×104 | 38 |
细胞 | 磷酸缓冲液 | AD/CMV-GFP | AD/gTRAIL | AD/GT-TRAIL+AD/PGK-GV16 | ||||
GFP+% | 凋亡% | GFP+% | 凋亡% | GFP+% | 凋亡% | GFP+% | 凋亡% | |
Lovo | 0.8 | 1.7 | 54.2 | 2.5 | 64.7 | 67.2 | 3.7 | 70.8 |
A549 | 0.3 | 1.9 | 91.1 | 5.6 | 87.4 | 30.2 | 1.9 | 53.8 |
DLD1 | 1.1 | 8.9 | 72.2 | 3.6 | 56.5 | 77.5 | 2.2 | 72.8 |
H460 | 0.9 | 4.4 | 71.1 | 4.0 | 61.3 | 32.3 | 3.7 | 34.3 |
NHPH | 0.2 | 2.4 | 50.2 | 2.4 | 0.2 | 2.8 | 0.2 | 30.6 |
NHFB | 0.4 | 0.7 | 37.0 | 0.4 | 0.5 | 2.0 | 0.3 | 3.5 |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011185252A CN1147587C (zh) | 2001-05-30 | 2001-05-30 | 一种增强细胞特异性目的基因表达的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB011185252A CN1147587C (zh) | 2001-05-30 | 2001-05-30 | 一种增强细胞特异性目的基因表达的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1388247A true CN1388247A (zh) | 2003-01-01 |
CN1147587C CN1147587C (zh) | 2004-04-28 |
Family
ID=4663247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011185252A Expired - Fee Related CN1147587C (zh) | 2001-05-30 | 2001-05-30 | 一种增强细胞特异性目的基因表达的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1147587C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101649319B (zh) * | 2009-09-09 | 2011-11-30 | 陕西师范大学 | 肿瘤特异嵌合启动子及其构建方法和应用 |
WO2019134692A1 (zh) * | 2018-01-08 | 2019-07-11 | 张晋宇 | 用于筛选抗肿瘤物质的系统及方法 |
CN113436683A (zh) * | 2020-03-23 | 2021-09-24 | 北京合生基因科技有限公司 | 筛选候选插入片段的方法和系统 |
CN114072516A (zh) * | 2019-05-30 | 2022-02-18 | 磨石生物公司 | 经修饰的腺病毒 |
-
2001
- 2001-05-30 CN CNB011185252A patent/CN1147587C/zh not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101649319B (zh) * | 2009-09-09 | 2011-11-30 | 陕西师范大学 | 肿瘤特异嵌合启动子及其构建方法和应用 |
WO2019134692A1 (zh) * | 2018-01-08 | 2019-07-11 | 张晋宇 | 用于筛选抗肿瘤物质的系统及方法 |
CN110016464A (zh) * | 2018-01-08 | 2019-07-16 | 张晋宇 | 用于筛选抗肿瘤物质的系统及方法 |
CN111556897A (zh) * | 2018-01-08 | 2020-08-18 | 张晋宇 | 用于筛选抗肿瘤物质的系统及方法 |
CN114072516A (zh) * | 2019-05-30 | 2022-02-18 | 磨石生物公司 | 经修饰的腺病毒 |
CN113436683A (zh) * | 2020-03-23 | 2021-09-24 | 北京合生基因科技有限公司 | 筛选候选插入片段的方法和系统 |
Also Published As
Publication number | Publication date |
---|---|
CN1147587C (zh) | 2004-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103614416A (zh) | 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途 | |
Barbellido et al. | Gene therapy in the management of oral cancer: Review of the literature | |
CN102985094B (zh) | 一种重组肿瘤疫苗及其生产方法 | |
KR20010031762A (ko) | 유전자요법을 위한 과열 유도 발현 벡터 및 그의 이용 방법 | |
CN1147587C (zh) | 一种增强细胞特异性目的基因表达的方法 | |
Azatian et al. | Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas | |
WO2020238427A1 (zh) | 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用 | |
CN103055325A (zh) | 结直肠癌特异性的基因-病毒治疗药物 | |
CN1259106C (zh) | 一种抗癌靶向基因病毒药物的制备方法 | |
CN101643749B (zh) | 腺相关病毒载体及其制备方法和应用 | |
AU2001294793B2 (en) | Viruses targeted to hypoxic cells and tissues | |
CN102994550B (zh) | 在动物细胞或动物组织中表达外源基因的方法 | |
Choi et al. | Enhanced tumor targeting and timely viral release of mesenchymal stem cells/oncolytic virus complex due to GRP78 and inducible E1B55K expressions greatly increase the antitumor effect of systemic treatment | |
CN111500632B (zh) | 表达st13和trail的溶瘤腺病毒构建及其应用 | |
CN108517335B (zh) | 一种肝细胞miR-199b低表达的慢病毒表达载体及其构建方法 | |
TWI819203B (zh) | 經修飾腺病毒及含有其之醫藥 | |
US5863794A (en) | SV40 viral vectors for targeted integration into cells | |
CN1570122A (zh) | 用于原发性肝癌基因治疗的腺病毒载体及使用方法 | |
CN101502659A (zh) | Krüppel样转录因子4的新用途 | |
CN117899238A (zh) | Pglyrp2基因的用途及其相关药物 | |
CN1327000C (zh) | 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒 | |
CN117430688A (zh) | 一种nfe2l1蛋白的ntd多肽及其在制备抗肿瘤药物中的用途 | |
CN115651932A (zh) | 一种靶向消化道肿瘤双靶向溶瘤腺病毒的构建方法及其应用 | |
CN116334038A (zh) | 一种dna表达增强因子及其应用 | |
CN113943715A (zh) | 一种重组溶瘤基因腺病毒及其构建方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG DONGFANG GENE BIOLOGICAL PRODUCTS CO., L Free format text: FORMER OWNER: FANG BINGLIANG Effective date: 20060519 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060519 Address after: 313300 Anji Zhejiang health medical park Patentee after: Zhejiang Orient Gene Biotech Co., Ltd. Address before: 100029 Beijing City, Chaoyang District Hui Xin Nan Li Hospital No. 5 2-3-203 Patentee before: Fang Bingliang |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method of strengthening specific destination gene expression of cell Effective date of registration: 20130710 Granted publication date: 20040428 Pledgee: Anji County Rural Credit Cooperative Association Pledgor: Zhejiang Orient Gene Biotech Co., Ltd. Registration number: 2013990000445 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20161020 Granted publication date: 20040428 Pledgee: Anji County Rural Credit Cooperative Association Pledgor: Zhejiang Orient Gene Biotech Co., Ltd. Registration number: 2013990000445 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170811 Address after: Health and medicine Industrial Park Economic Development Zone of Anji County of Zhejiang province Huzhou City Kyrgyzstan road 313300 Patentee after: Fang Bingliang Address before: 313300 Anji Zhejiang health medical park Patentee before: Zhejiang Orient Gene Biotech Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040428 Termination date: 20190530 |